Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Ronald Lee Korn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1141-5749; OpenAlex author ID A5004915418. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag232↗
  2. Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib. Co-author DOI 10.3390/biomedicines10112705↗
  3. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. First author DOI 10.3389/fonc.2021.678617↗
  4. 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Co-author DOI 10.1186/s40644-017-0125-5↗
  5. Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. First author DOI 10.1093/annonc/mdw177↗
  6. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2010↗
  7. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  8. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Co-author DOI 10.1200/jco.2011.36.5742↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 6 shared papers, 2011–2026 · strength 0.54
  2. Erkut Hasan Borazanci · 3 shared papers, 2021–2026 · strength 0.49
  3. Gayle Jameson · 2 shared papers, 2022–2026 · strength 0.38
  4. Syed Rahmanuddin · 2 shared papers, 2021–2026 · strength 0.33
  5. Albert Amini · 1 shared paper, 2026 · strength 0.22
  6. Alexa F. Viniotis · 1 shared paper, 2026 · strength 0.22
  7. Ronald M. Evans · 1 shared paper, 2026 · strength 0.22
  8. Gehan Botrus · 1 shared paper, 2022 · strength 0.16
  9. Pedro Luiz Serrano Usón · 1 shared paper, 2022 · strength 0.16
  10. Ramesh K. Ramanathan · 3 shared papers, 2011–2017 · strength 0.13
  11. Derek Cridebring · 1 shared paper, 2021 · strength 0.11
  12. Vincent M. Chung · 1 shared paper, 2021 · strength 0.11
  13. Eugene Jon Koay · 1 shared paper, 2021 · strength 0.11
  14. Ajay Goel · 1 shared paper, 2021 · strength 0.11
  15. Mitesh J. Borad · 2 shared papers, 2011–2017 · strength 0.10
  16. Markus Frederic Renschler · 1 shared paper, 2017 · strength 0.08
  17. R.K. Ramanathan · 1 shared paper, 2016 · strength 0.08
  18. Elena Gabriela Chiorean · 1 shared paper, 2016 · strength 0.08
  19. Sergei Tjulandin · 1 shared paper, 2016 · strength 0.05
  20. Craig Devoe · 1 shared paper, 2016 · strength 0.05
  21. Sunil R. Hingorani · 1 shared paper, 2016 · strength 0.05
  22. Neeta D. Pandit-Taskar · 1 shared paper, 2015 · strength 0.03
  23. William A. Wegener · 1 shared paper, 2015 · strength 0.03
  24. Alexander Starodub · 1 shared paper, 2015 · strength 0.03
  25. Fa-Chyi Lee · 1 shared paper, 2015 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.